Compare AU
Compare CURE vs. VBND
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the Vanguard Global Aggregate Bond Index (Hedged) ETF (VBND). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | VBND | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 82 | 122 |
Median incremental investment | $619.50 | $1,027.52 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,323.41 | $2,405.80 |
Average age group | > 35 | > 35 |
Key Summary
CURE | VBND | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | VBND.AX was created on 2017-10-10 by Vanguard. The fund's investment portfolio concentrates primarily on investment grade fixed income. Vanguard Global Aggregate Bond Index (Hedged) ETF seeks to track the return of the Bloomberg Barclays Global Aggregate Float-Adjusted and Scaled Index hedged into Australian dollars before taking into account fees, expenses and tax |
Top 3 holdings | Natera Inc (3.41 %) Incyte Corp (2.94 %) Gilead Sciences Inc (2.88 %) | United States Treasury Note/Bond 4.25 2024-12-31 (0.39 %) United States Treasury Note/Bond 4.5 2024-11-30 (0.37 %) Italy Buoni Poliennali Del Tesoro 3.4 2025-03-28 (0.33 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0.45 % | 0.2 % |
Key Summary
CURE | VBND | |
|---|---|---|
Issuer | Global X | Vanguard |
Tracking index | S&P Biotechnology Select Industry | Bloomberg Barclays Global Aggregate Float Adjusted Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.2 % |
Price | $49.94 | $41.84 |
Size | $38.065 million | $4.373 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.24 % | 3.65 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 12/10/2017 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | VBND | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 82 | 122 |
Median incremental investment | $619.50 | $1,027.52 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,323.41 | $2,405.80 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | VBND | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | VBND |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |